The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Can the gut microbiome predict response to CAR T-cell therapy in lymphoma?
Sandrine Roulland, PharmD, PhD, Center for Immunology of Marseille-Luminy (CIML), Marseille, France, discusses the growing role of the gut microbiome in predicting response to CAR T-cell therapy in lymphoma. She explains how microbiome profiling may help identify patients most likely to benefit from treatment, while highlighting ongoing efforts to develop practical blood-based biomarkers that could support future clinical decision-making. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
